BioCryst Pharmaceuticals (BCRX) News Today $7.45 +0.39 (+5.52%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Decreases By 9.1%January 20 at 2:09 AM | americanbankingnews.comJPMorgan Chase & Co. Trims Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)JPMorgan Chase & Co. lessened its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 22.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 577,129 shares of the biotechnology company's stock after selling 1January 18 at 3:19 AM | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significant Decline in Short InterestBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 15,720,000 shares, a decline of 9.1% from the December 15th total of 17,290,000 shares. Based on an average trading volume of 2,050,000 shares, the short-interest ratio is presently 7.7 days.January 18 at 1:38 AM | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 3.4% - Time to Sell?BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 3.4% - What's Next?January 16, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 3.4% - Here's What HappenedBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 3.4% - What's Next?January 14, 2025 | marketbeat.comEvercore ISI Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $12.00January 14, 2025 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $15.00 at Needham & Company LLCJanuary 14, 2025 | americanbankingnews.comBioCryst Pharmaceuticals Releases Positive Financial Results and Guidance for 2025January 14, 2025 | americanbankingnews.comBioCryst price target raised to $12 from $10 at Evercore ISIJanuary 14, 2025 | markets.businessinsider.comBioCryst: Strong Sales Performance and Future Growth Projections Lead to Buy RatingJanuary 14, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $12.00 Price Target at Evercore ISIEvercore ISI raised their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday.January 13, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $15.00 Price Target at Needham & Company LLCNeedham & Company LLC increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday.January 13, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Time to Buy?January 12, 2025 | americanbankingnews.comBioCryst Pharmaceuticals: Continued Growth Driven by Orladeyo and Strategic Initiatives, Targeting $1 Billion Sales by 2030January 11, 2025 | markets.businessinsider.comBioCryst’s Strong Growth Prospects and Pipeline Developments Support Buy RatingJanuary 11, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)January 10, 2025 | finanznachrichten.deBioCryst (BCRX) Receives a Buy from RBC CapitalJanuary 10, 2025 | markets.businessinsider.comBioCryst Prel. Q4, FY24 Total Revenue, ORLADEYO Net Revenue IncreasesJanuary 10, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Here's WhyBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Time to Buy?January 10, 2025 | marketbeat.comBioCryst Pharmaceuticals Inc (BCRX) Projects Strong Revenue Growth and New Drug Developments ...January 10, 2025 | gurufocus.comBioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)January 10, 2025 | globenewswire.comBioCryst reports inducement grants under Nasdaq listing ruleJanuary 7, 2025 | markets.businessinsider.comBioCryst to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comBioCryst Pharmaceuticals Inc (BCRX) Announces Stock Options and RSUs for New EmployeesJanuary 6, 2025 | gurufocus.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 6, 2025 | globenewswire.comPrincipal Financial Group Inc. Acquires 375,890 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Principal Financial Group Inc. lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 1,058.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 411,414 sharesJanuary 4, 2025 | marketbeat.comShort Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Drops By 10.7%BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) saw a large decline in short interest in December. As of December 15th, there was short interest totalling 17,290,000 shares, a decline of 10.7% from the November 30th total of 19,360,000 shares. Based on an average trading volume of 1,990,000 shares, the days-to-cover ratio is presently 8.7 days.December 31, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given an average rating of "Moderate Buy" by the five brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buyDecember 29, 2024 | marketbeat.comThe 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%December 27, 2024 | finance.yahoo.comFranklin Resources Inc. Has $1.97 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Franklin Resources Inc. lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 177.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 263,748 shares of the bDecember 27, 2024 | marketbeat.comGeode Capital Management LLC Buys 127,708 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Geode Capital Management LLC grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,837,985 shares of the biotechnology company's stock aftDecember 25, 2024 | marketbeat.comWellington Management Group LLP Invests $819,000 in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Wellington Management Group LLP bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 107,820 shares of the biotechnology company's stock, valDecember 20, 2024 | marketbeat.comXTX Topco Ltd Has $241,000 Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)XTX Topco Ltd lowered its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 79.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,670 shares of the biotechnology company's sDecember 19, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by State Street CorpState Street Corp reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 5.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,849,588 shares of the biotechnology company's stock after sellDecember 18, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - What's Next?BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - What's Next?December 17, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Verition Fund Management LLCVerition Fund Management LLC lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 72.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 39,520 shares of the biotechnology company's stock after selling 102,839 sharesDecember 15, 2024 | marketbeat.comBioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A BuyDecember 9, 2024 | seekingalpha.comTwo Sigma Advisers LP Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Two Sigma Advisers LP raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 13.6% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,181,012 shares of the biotechnology company's stock aftDecember 9, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)The Manufacturers Life Insurance Company grew its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 40.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 299December 9, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 102,860 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Charles Schwab Investment Management Inc. grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 5.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,887,994 shares of the bioteDecember 9, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $2.79 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Jacobs Levy Equity Management Inc. lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 50.3% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 367,514 shares of the biotechnology company's stock after selling 372,085December 8, 2024 | marketbeat.comBioCryst price target raised to $18 from $16 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comBNP Paribas Financial Markets Buys 409,938 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)BNP Paribas Financial Markets raised its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 472.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 496,784 shares of the biotechnology compaDecember 5, 2024 | marketbeat.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 4, 2024 | globenewswire.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from AnalystsShares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recDecember 4, 2024 | marketbeat.comCinctive Capital Management LP Makes New $2.08 Million Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Cinctive Capital Management LP acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 273,959 shares of the biotechnology company's stock, valued at approxiDecember 3, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is Caligan Partners LP's 7th Largest PositionCaligan Partners LP lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 43.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,583,585 shares of the biotechnology company's stockDecember 1, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Lifted by Fisher Asset Management LLCFisher Asset Management LLC boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 16.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,338,062 shares of the biotNovember 28, 2024 | marketbeat.comAlgert Global LLC Raises Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Algert Global LLC raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 46.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 516,209 shares of the biotechnology company's stock after purchasing an additNovember 26, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Lowers Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Connor Clark & Lunn Investment Management Ltd. cut its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 12.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 682,324 shares of the biotecNovember 24, 2024 | marketbeat.com Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Media Mentions By Week BCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼0.820.46▲Average Medical News Sentiment BCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼75▲BCRX Articles Average Week Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IONS News Today ALKS News Today FOLD News Today LGND News Today GERN News Today MNKD News Today DVAX News Today CLDX News Today NVAX News Today INVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCRX Stock Alerts